Fibrosis regression induced by intravenous gammaglobulin treatment

H. Amital, E. Rewald, Y. Levy, Y. Bar-Dayan, R. Manthorpe, P. Engervall, Y. Sherer, P. Langevitz, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjögren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.

Original languageEnglish
Pages (from-to)175-177
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume62
Issue number2
DOIs
StatePublished - 1 Feb 2003

Fingerprint

Dive into the research topics of 'Fibrosis regression induced by intravenous gammaglobulin treatment'. Together they form a unique fingerprint.

Cite this